Edition:
United Kingdom

BiondVax Pharmaceuticals Ltd (BVXV.OQ)

BVXV.OQ on NASDAQ Stock Exchange Capital Market

4.99USD
14 Dec 2017
Change (% chg)

$-0.21 (-4.04%)
Prev Close
$5.20
Open
$5.13
Day's High
$5.13
Day's Low
$4.99
Volume
2,954
Avg. Vol
6,803
52-wk High
$10.75
52-wk Low
$3.04

Chart for

About

BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company. The Company holds a worldwide exclusive license granted by Yeda Research and Development Ltd., the commercial arm of the Weizmann Institute, Israel, for developing, manufacturing and commercializing the flu vaccine. BiondVax Pharmaceuticals Ltd develops a... (more)

Overall

No Ratios Available.

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Biondvax Pharmaceuticals Ltd Reports Qtrly Loss Per Share of NIS 0.01 ‍​

* BIONDVAX PHARMACEUTICALS LTD - QTRLY LOSS PER SHARE NIS 0.01 ‍​ Source text for Eikon: Further company coverage:

28 Nov 2017

BRIEF-BiondVax and NIH sign clinical trial agreement for phase 2 trial for universal flu vaccine

* BiondVax and NIH sign clinical trial agreement for a phase 2 trial in the U.S. with BiondVax's universal flu vaccine

20 Nov 2017

BRIEF-Eastern Capital reports 7.3 pct passive stake in Biondvax Pharmaceuticals

* Eastern capital ltd reports 7.3 percent passive stake in Biondvax Pharmaceuticals Ltd as of September 18, 2017 - SEC Filing Source text: (http://bit.ly/2wSBhH6) Further company coverage:

26 Sep 2017

BRIEF-Ibex Investors reports 5.5 pct passive stake in BiondVax Pharma

* Ibex Investors LLC reports 5.5 percent passive stake in BiondVax Pharmaceuticals Ltd as of Sept 14, 2017 - SEC filing Source text: (http://bit.ly/2fGw3nu) Further company coverage:

22 Sep 2017

BRIEF-BiondVax announces pricing of public offering of American Depositary Shares

* BiondVax announces pricing of public offering of American Depositary Shares

14 Sep 2017

BRIEF-BiondVax announces public offering of American Depositary Shares

* BiondVax announces public offering of American Depositary Shares

13 Sep 2017

BRIEF-BiondVax Pharmaceuticals reports qtrly loss per share of NIS 0.07

* Qtrly loss per share NIS 0.07 Source text for Eikon: Further company coverage:

31 Aug 2017

BRIEF-Dual-listed BiondVax to voluntarily delist from Tel Aviv Stock Exchange

* Dual-listed BiondVax to voluntarily delist from Tel Aviv Stock Exchange

31 Aug 2017

BRIEF-BiondVax receives additional grant funding

* BiondVax Pharmaceuticals Ltd - ‍Israel innovation authority agreed to fund upto 40% of a nis 2.7 million budget towards ongoing development of M-001 Source text for Eikon: Further company coverage:

14 Aug 2017

BRIEF-Biondvax Pharmaceuticals: trial meets both primary endpoints

* Biondvax reports positive Phase 2b clinical trial results for its universal flu vaccine

20 Jul 2017

Earnings vs. Estimates